- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07909226
Lactate/Albumin Ratio and Mortality in Respiratory Failure
The Prognostic Role of the Lactate/Albumin Ratio in Predicting 28-Day Mortality in Patients Admitted to the Intensive Care Unit With a Diagnosis of Respiratory Failure
This retrospective observational study aims to evaluate the association between the lactate-to-albumin ratio (LAR) measured at ICU admission and 28-day mortality in adult patients admitted to the intensive care unit with acute respiratory failure. The study will also compare the prognostic value of LAR with that of existing clinical and laboratory parameters.
연구 개요
상태
상세 설명
Acute respiratory failure is a common cause of intensive care unit (ICU) admission and is associated with high short-term mortality. Early risk stratification is important for guiding treatment intensity and resource allocation. Serum lactate reflects tissue hypoperfusion and impaired oxygen utilization, whereas serum albumin is a marker of nutritional status, systemic inflammation, and capillary leak. The lactate-to-albumin ratio (LAR) combines these two readily available laboratory parameters and has been proposed as a prognostic marker in critically ill patients. However, its prognostic value in patients with acute respiratory failure has not been well established.
This is a single-center, retrospective observational cohort study conducted at Kocaeli City Hospital, including adult patients (≥18 years) admitted to the ICU with acute respiratory failure between April 2023 and June 2026. Data will be obtained from the hospital information system and ICU records.
The primary objective is to evaluate the association between LAR at ICU admission and 28-day all-cause mortality. The secondary objective is to compare the prognostic performance of LAR with that of serum lactate alone, serum albumin alone, and established severity scores (e.g., APACHE II, SOFA).
The following data will be collected: demographic characteristics, comorbidities, cause of respiratory failure, need for invasive mechanical ventilation, severity scores, laboratory parameters (including lactate and albumin measured at ICU admission), ICU and hospital length of stay, and 28-day survival status. LAR will be calculated as serum lactate (mmol/L) divided by serum albumin (g/dL).
Patients will be grouped as survivors and non-survivors at 28 days. The association between LAR and mortality will be assessed using logistic regression and/or Cox proportional hazards models adjusted for relevant confounders. Discriminative ability will be evaluated with receiver operating characteristic (ROC) curve analysis, and the optimal cut-off value will be determined. AUC values of LAR and the comparator parameters will be compared.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Aytuğ Yıldız, MD
- 전화번호: +905445306369
- 이메일: aytugyildiz9093@gmail.com
연구 장소
-
-
Kocaeli
-
İzmit, Kocaeli, 터키 (Türkiye), 41100
- 모병
- Kocaeli City Hospital
-
연락하다:
- Ahmet Yüksek, MD
- 전화번호: 05326580351
- 이메일: mdayuksek@hotmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult patients (≥18 years) admitted for the first time to the intensive care unit of the Department of Anesthesiology and Reanimation, Kocaeli City Hospital, Turkey, with a diagnosis of acute respiratory failure between April 2023 and June 2026. Data will be retrospectively obtained from the hospital information system and patient records.
설명
Inclusion Criteria:
- Age 18 years or older
- First ICU admission with a diagnosis of acute respiratory failure between April 2023 and June 2026
Exclusion Criteria:
- Missing data in the hospital information system
- Known terminal-stage solid organ malignancy
- Laboratory data (lactate/albumin) obtained after albumin replacement
- ICU stay shorter than 24 hours
- Death within the first 24 hours of ICU admission
- Pregnancy
- Cardiopulmonary resuscitation within 24 hours before ICU admission
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: RETROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
ICU patients with acute respiratory failure
Adult (≥18 years) patients admitted to the ICU with acute respiratory failure between April 2023 and June 2026, in whom lactate and albumin were measured at ICU admission. LAR will be calculated and its association with 28-day mortality will be evaluated. |
In this observational cohort study, no experimental clinical intervention was administered. The primary exposure variable (prognostic marker/predictor) evaluated is the Lactate-to-Albumin Ratio (LAR), calculated from serum lactate level (mmol/L) divided by serum albumin level (g/dL) measured within the first 24 hours of intensive care unit admission. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Prognostic performance of LAR for 28-day mortality
기간: 28 days after ICU admission
|
Discriminative ability of LAR at ICU admission for predicting 28-day mortality, assessed by the area under the receiver operating characteristic curve (AUC), with determination of the optimal cut-off value. |
28 days after ICU admission
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
7-day mortality
기간: 7 days after ICU admission
|
Death from any cause within 7 days after ICU admission. |
7 days after ICU admission
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Comparison of LAR with serum lactate and serum albumin alone
기간: 28 days after ICU admission
|
Comparison of the predictive performance (AUC) of LAR with that of lactate alone and albumin alone for 28-day mortality. |
28 days after ICU admission
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Ahmet Yüksek, MD, Kocaeli City Hospital
- 수석 연구원: Aytuğ Yıldız, MD, Kocaeli City Hospital
간행물 및 유용한 링크
일반 간행물
- Tong H, Zhou W, Wu L, Zhu Q. Response to: Interpreting the prognostic value of the lactate-to-albumin ratio in severe acute pancreatitis. Saudi J Gastroenterol. 2026 Oct 13. doi: 10.4103/sjg.sjg_392_26. Online ahead of print. No abstract available.
- C HP, Kumar PA. Lactate-albumin ratio as an early predictor of mortality in critically ill children: A prospective cohort study. Eur J Pediatr. 2026 Oct 16;185(11):854. doi: 10.1007/s00431-026-07525-x.
- Arslan Aksu E, Ozdemir L, Gegin S, Ozdemir B. Prognostic value of systemic inflammatory markers in patients with malignancy-associated pulmonary thromboembolism: A retrospective observational study. Medicine (Baltimore). 2026 Oct 16;105(42):e51137. doi: 10.1097/MD.0000000000051137.
- Mu Y, Tang H, Zeng Y, Wang Q, Huang T, Li W, Wu X, Pi S. LDAR shows more consistent prognostic performance than other albumin-derived indices for 28-day ICU mortality in critically ill patients with urosepsis: evidence from a dual-cohort retrospective study. Front Med (Lausanne). 2026 Oct 1;13:1915095. doi: 10.3389/fmed.2026.1915095. eCollection 2026.
- Li G, Zhang D, Yuan F, Li M, Wang Y, Zhou J, Fu Y. Association of the lactate dehydrogenase-to-albumin ratio with all-cause and non-relapse mortality in patients with aGVHD after allogeneic HSCT: a single-center retrospective cohort study. Front Immunol. 2026 Oct 9;17:1936503. doi: 10.3389/fimmu.2026.1936503. eCollection 2026.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 2026-174
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The study data may be shared upon an appropriate request and institutional approval. It is not publicly available.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .